Article Details
Retrieved on: 2024-11-17 02:14:16
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Intellia Therapeutics' positive Phase 1 trial results for a CRISPR-based gene editing therapy, nex-z, in treating ATTR amyloidosis. The therapy reduces transthyretin protein, showing potential to stabilize or improve conditions linked to protein misfolding, like cardiomyopathy and polyneuropathy, relating to the key concept of 'protein folding.' Tags highlight related diseases and technologies.
Article found on: www.stocktitan.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here